Literature DB >> 3293155

Survey of chemotherapy of metastatic renal cancer.

J Kühböck1.   

Abstract

A critical survey is made of cytotoxic chemotherapy of metastatic renal cancer. On the basis of representative summaries, only a few substances such as vinblastine, CCNU, hydroxyurea, and ifosfamide seem to act with some degree of success, but no specific antirenal cancer agent has as yet become available. This outline should provide a more realistic view of the therapeutic possibilities and of the limits of cytostatic chemotherapy in the metastatic phase of renal cancer. It is postulated that chemotherapy should feature more prominently in future therapeutic strategies. Newer cytostatic substances, i.e., second-generation alkylating agents and anthracyclines as well as platinum analogues, may present an advance with regard to side effects and tolerance but are discouraging with regard to their therapeutic efficiency in metastatic renal cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293155

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  2 in total

1.  Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.

Authors:  J T Donaldson; T E Keane; S H Poulton; P J Walther
Journal:  Urol Res       Date:  1990

2.  A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.

Authors:  B R Murphy; S M Rynard; L H Einhorn; P J Loehrer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.